

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ikemoto et al.

Application No. 10/086,076

Filed: February 28, 2002

Art Unit: 1621

Examiner: Samuel A. Barths

For: PRODUCTION METHOD OF CITALOPRAM,
INTERMEDIATE THEREFOR AND PRODUCTION
METHOD OF THE INTERMEDIATE

REQUEST FOR REFUND

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Attn: Refund Section, Accounting Division
Office of Finance

Sir:

Refund Request

- ☒ The Patent Office erroneously charged our firm's Deposit Account No. 12-1216 for an Information Disclosure Fee (\$180) on June 5, 2006. The submission of June 5, 2006, is a resubmission of the Information Disclosure Statement originally submitted on August 27, 2003. Therefore, no fees are required.
- ☒ This request for refund is made within two years of the date a fee was paid in this application on June 5, 2006 in the amount of \$180.

Fees Paid

- ☐ Filing Fee
- ☐ Surcharge for filing the basic filing fee on a date later than the filing date of the application
- ☐ Surcharge for filing the oath or declaration later than the filing date of the application
- ☒ Surcharge for filing the Information Disclosure Statement after the issuance of a first Office Action

AMOUNT OF
REFUND REQUESTED

\$

\$

\$


\$180.00

TOTAL REFUND REQUESTED


\$180.00

Please make the refund by ☒ crediting Deposit Account No. 12-1216 or ☐ forwarding a check in the amount of the refund to the address below.

Respectfully submitted,


John Kilyk, Jr., Reg. No. 38,763
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: August 25, 2006

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8			
I hereby certify that this Request for Refund and all accompanying documents are, on the date indicated below, <input checked="" type="checkbox"/> being facsimile transmitted to the U.S. Patent and Trademark Office, Attention: Refund Section, Accounting Division, Office of Finance, Facsimile Number 571-273-6500			
Name (Print/Type)	John Kilyk, Jr.		
Signature		Date	August 25, 2006

RECEIVED
CENTRAL FAX CENTER

JUN 05 2006

PATENT
Attorney Docket No. 215851

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ikemoto et al.

Application No. 10/086,076

Group Art Unit: 1621

Filed: February 28, 2002

Examiner: M. L. Shippen

For: PRODUCTION METHOD OF CITALOPRAM,
INTERMEDIATE THEREFOR AND PRODUCTION
METHOD OF THE INTERMEDIATE

COPY

INFORMATION DISCLOSURE STATEMENT

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

- ☐ within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

06/06/2006 AKELECH1 00000074 121216 10086076

01 FC:1806 180.00 DA

Adjustment date: 09/01/2006 ZJUHARI
06/06/2006 AKELECH1 00000074 121216 10086076
01 FC:1806 180.00 CR